Cornerstone Robotics vs Genentech

Side-by-side comparison of AI visibility scores, market position, and capabilities

Genentech leads in AI visibility (85 vs 29)
Cornerstone Robotics logo

Cornerstone Robotics

EmergingMedTech

Multi-Arm Surgical Robotics

Raised $200M oversubscribed (Nov 2025) backed by Hong Kong Investment Corporation and sovereign wealth funds. China NMPA-approved. UK colorectal/urologic clinical trial launched.

AI VisibilityBeta
Overall Score
D29
Category Rank
#1 of 1
AI Consensus
64%
Trend
up
Per Platform
ChatGPT
26
Perplexity
21
Gemini
24

About

Cornerstone Robotics is a surgical robotics company whose Sentire Endoscopic Surgical System uses multiple robotic arms to enable minimally invasive surgery with enhanced dexterity beyond single-arm laparoscopic systems. The company raised $200 million in an oversubscribed round in November 2025, backed by the Hong Kong Investment Corporation and global sovereign wealth funds. Sentire has received China National Medical Products Administration (NMPA) approval and launched UK clinical trials for colorectal and urologic procedures in 2025, with 2026 as its international commercialization ramp year.

Full profile
Genentech logo

Genentech

LeaderLife Sciences & BioTech

Biopharmaceuticals

Roche subsidiary and founding biotech; invented the biologics industry with recombinant DNA. Blockbuster oncology franchise includes Herceptin, Avastin, Rituxan, and Tecentriq.

AI VisibilityBeta
Overall Score
A85
Category Rank
#1 of 2
AI Consensus
57%
Trend
up
Per Platform
ChatGPT
77
Perplexity
95
Gemini
83

About

Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching the modern biotechnology industry. Acquired by Roche in 2009 for $46.8 billion, Genentech continues to operate with significant R&D autonomy as the US hub for Roche's pharmaceutical innovation.\n\nThe company is best known for pioneering cancer biologics, developing Herceptin (trastuzumab) for HER2-positive breast cancer, Avastin (bevacizumab) for multiple cancers, Rituxan (rituximab) for lymphoma, and Tecentriq (atezolizumab) for PD-L1 immunotherapy. Its discovery engine spans oncology, neuroscience, ophthalmology, and immunology with a robust early-stage pipeline leveraging AI-assisted target identification.\n\nGenentech generates tens of billions in annual revenue through Roche's Pharmaceuticals Division and remains one of the most productive biotech research sites in the world, consistently ranked among top employers in life sciences. The South San Francisco campus employs over 13,000 scientists, clinicians, and engineers, anchoring the Bay Area as a global biotech hub.

Full profile

AI Visibility Head-to-Head

29
Overall Score
85
#1
Category Rank
#1
64
AI Consensus
57
up
Trend
up
26
ChatGPT
77
21
Perplexity
95
24
Gemini
83
36
Claude
87
22
Grok
79

Key Details

Category
Multi-Arm Surgical Robotics
Biopharmaceuticals
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Cornerstone Robotics
Multi-Arm Surgical Robotics
Only Genentech
Biopharmaceuticals
Genentech is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.